Search results
Results from the WOW.Com Content Network
Portola Pharmaceuticals is an American clinical stage biotechnology company that researches, develops, and commercializes drugs. The company focuses primarily on drugs used in the treatment of thrombosis and hematological malignancies . [ 2 ]
He has been a minority owner of the Los Angeles Lakers since 2010, and since June 2018, he has been the owner and executive chairman of the Los Angeles Times. [8] Soon-Shiong's net worth is $6.2 billion as of 2024. [9] He has been called the richest man in Los Angeles and one of the wealthiest doctors in the world. [10]
Robert W. Duggan (born 1944) is an American billionaire, entrepreneur, philanthropist, biotech executive and health care executive.He is the former CEO of biopharmaceutical company Pharmacyclics [2] and was previously CEO of surgical systems maker Computer Motion from 1997 to 2003. [3]
Pharmacological Reviews is a quarterly peer-reviewed scientific journal publishing review articles on all aspects of pharmacology and related topics. It is published by the American Society for Pharmacology and Experimental Therapeutics. The editor-in-chief is Lynette C. Daws (The University of Texas Health Science Center at San Antonio).
Portola (/ p ɔːr ˈ t oʊ l ə / por-TOH-lə) is the only incorporated city in Plumas County, California, United States. The population was 2,104 at the 2010 census, down from 2,227 at the 2000 census. Portola is located on the Middle Fork of the Feather River and was named after Spanish explorer Gaspar de Portolá, [5] although he did not ...
Martine Aliana Rothblatt is an American lawyer, author, and entrepreneur. Rothblatt graduated from University of California, Los Angeles with J.D. and M.B.A. degrees in 1981, then began to work in Washington, D.C., first in the field of communications satellite law, then in bioethics and biomedicine. [3]
PTC Therapeutics’ therapy, known as PTC518, is an oral medication designed to reduce the production of the mutant protein linked to the genetic mutation responsible for the disease. [15] This mutant protein is believed to contribute to neuronal death, driving disease progression. [ 16 ]
Former CEO of Pernix Therapeutics, John Sedor, filed a claim in bankruptcy court for the amount of $1,534,375. John Sedor willingly and knowingly misled employees and shareholders of the company while backdoor negotiating an exit plan for Highbridge Capital Management to inflate the stock price a week before the bankruptcy was declared.